Scholar Rock Holding Corp (SRRK)
27.49
+0.11
(+0.40%)
USD |
NASDAQ |
Nov 14, 16:00
27.50
+0.01
(+0.04%)
After-Hours: 20:00
Scholar Rock Research and Development Expense (Quarterly): 42.37M for June 30, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 42.37M |
| March 31, 2024 | 43.09M |
| December 31, 2023 | 34.96M |
| September 30, 2023 | 30.34M |
| June 30, 2023 | 26.87M |
| March 31, 2023 | 29.74M |
| December 31, 2022 | 29.61M |
| September 30, 2022 | 33.39M |
| June 30, 2022 | 32.07M |
| March 31, 2022 | 29.37M |
| December 31, 2021 | 29.05M |
| September 30, 2021 | 31.26M |
| June 30, 2021 | 25.60M |
| March 31, 2021 | 22.55M |
| December 31, 2020 | 21.78M |
| Date | Value |
|---|---|
| September 30, 2020 | 18.38M |
| June 30, 2020 | 17.00M |
| March 31, 2020 | 16.90M |
| December 31, 2019 | 14.06M |
| September 30, 2019 | 15.70M |
| June 30, 2019 | 13.72M |
| March 31, 2019 | 10.74M |
| December 31, 2018 | 10.12M |
| September 30, 2018 | 8.061M |
| June 30, 2018 | 11.42M |
| March 31, 2018 | 6.701M |
| December 31, 2017 | 6.887M |
| September 30, 2017 | 4.778M |
| June 30, 2017 | 4.711M |
| March 31, 2017 | 3.568M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
14.06M
Minimum
Dec 2019
43.09M
Maximum
Mar 2024
27.81M
Average
29.37M
Median
Mar 2022
Research and Development Expense (Quarterly) Benchmarks
| Cytokinetics Inc | -- |
| Regeneron Pharmaceuticals Inc | 1.272B |
| Ocugen Inc | 8.108M |
| Mirum Pharmaceuticals Inc | 32.67M |
| NeuroBo Pharmaceuticals Inc | 4.517M |